HCW Biologics Inc.
HCWB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 1.53 | 2.56 |
| FCF Yield | -38.74% | -46.45% | -0.70% | -0.43% |
| EV / EBITDA | -3.47 | -8.75 | -413.76 | -366.03 |
| Quality | ||||
| ROIC | -60.94% | -40.83% | -36.56% | -45.65% |
| Gross Margin | -1,094.35% | 20.00% | 20.00% | 20.00% |
| Cash Conversion Ratio | 0.71 | 1.70 | 1.60 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.15% | -39.79% | -26.55% | -27.45% |
| Free Cash Flow Growth | 1.29% | 6.59% | -19.18% | 0.51% |
| Safety | ||||
| Net Debt / EBITDA | -1.51 | -3.33 | -10.27 | -4.71 |
| Interest Coverage | -25.86 | -15.15 | -7.68 | -12.74 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,982.09 | -332,127.26 | -436,763.48 | -6,230.90 |